|
Clinical features
|
AM*(N = 11)
|
Non AM (N = 17)
|
p value
|
|---|
| |
Median (range)
|
Median (range)
| |
|---|
|
Age (years)
|
52 (36 to 63)
|
50 (20 to 63)
|
0.56
|
|
Duration of PsA (years)
|
12 (5 to 35)
|
10 (5 to 25)
|
0.51
|
|
Duration of psoriasis (years)
|
22 (11 to 49)
|
20 (5 to 50)
|
0.24
|
|
Weight (kg) mean (range)
|
78 (65 to 107)
|
83 (68 to 111)
|
0.42
|
|
Female:Male
|
3:8
|
8:9
|
0.44
|
|
Ethnicity: European
|
91%
|
88%
|
0.94
|
|
Medications
|
Number (%)
|
Number (%)
| |
|
Methotrexate
|
4 (36%)
|
11 (65%)
| |
|
NSAIDs
|
7 (64%)
|
10 (10%)
| |
|
Prednisone 5 to 20 mg/day
|
2 (18%)
|
2 (12%)
| |
|
Sulphasalazine 2 to 3 g/day
|
3 (28%)
|
5 (29%)
| |
|
Azathioprine 150 mg/day
|
0
|
1 (6%)
| |
|
Hydroxychloroquine 400 mg/day
|
0
|
1 (6%)
| |
|
Leflunomide 20 mg/day
|
1 (9%)
|
0
| |
|
Cyclosporin 100 mg/day
|
0
|
1 (6%)
| |
|
Disease activity
|
Median (range)
|
Median (range)
| |
|
Tender joint count
|
17 (1 to 40)
|
11 (4 to 51)
|
0.98
|
|
Swollen joint count
|
6 (0 to 33)
|
4 (0 to 9)
|
0.20
|
|
Pain score
|
35 (16 to 78)
|
45 (6 to 82)
|
0.47
|
|
HAQ score (n = 27)
|
1.1 (0 to 3.5)
|
0.7 (0 to 3)
|
0.26
|
|
PF-SF-36
|
52.5 (5 to 85)
|
65 (10 to 90)
|
0.39
|
|
ESR (mm/hour)
|
14 (1 to 43)
|
13 (2 to 86)
|
0.61
|
|
CRP (mg/litre) (n = 25)
|
11.6 (3 to 59)
|
4.9 (< 1 to 46)
|
0.26
|
|
DAS28-CRP (n = 23)
|
3.91 (2.6 to 5.7)
|
4.2 (2.3 to 6.2)
|
0.64
|
|
DAS28-ESR (n = 28)
|
4.2 (1.7 to 6.1)
|
4.0 (1.9 to 6.9)
|
0.61
|
|
Psoriatic nail severity score
|
11 (0 to 47)
|
8 (0 to 22)
|
0.19
|
|
PASI (n = 26)
|
0.6 (0 to 12)
|
1.8 (0 to 10.3)
|
0.84
|
- AM = arthritis mutilans, CRP = c-reactive protein, DAS28 – CRP = Disease Activity Score (28 swollen and tender joints, CRP, General Health VAS), DAS28 – ESR = Disease Activity Score (28 swollen and tender joints, ESR, General Health VAS), ESR = Erythrocyte Sedimentation Rate, HAQ = Health Assessment Questionnaire, non-AM = non-arthritis mutilans, NSAID = nonsteroidal anti-inflammatory drugs, PASI = Psoriasis Area and Severity Index, PF-SF-36 = Physical Function component of the Short Form 36 Questionnaire, PsA = psoriatic arthritis.
